Assessment, stratification, and monitoring of the risk for prescription opioid misuse and abuse in the primary care setting

Journal of Opioid Management

Volumn 7, Issue 6, 2011, Pages 467-482

  Brown, James ^a   Setnik, Beatrice ^b   Lee, Keung ^c   Wase, Linda ^d   Roland, Carl L ^b   Cleveland, Jody M ^b   Siegel, Sherry ^e   Katz, Nathaniel ^f,g  

^a Jena Medical   (United States)

^b PFIZER INC   (United States)

^c Randolph Medical Associates   (United States)

^d Archimedes Pharma US Inc   (United States)

^e Neurosciences Division   (United States)

^f Analgesic Solutions   (United States)

^g TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drug abuse; Illicit drugs; Morphine; Opioid analgesics; Primary care

Indexed keywords

MORPHINE SULFATE;

ADULT; AGED; ANALGESIA; ARTICLE; BEHAVIOR DISORDER; CHRONIC PAIN; DAILY LIFE ACTIVITY; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG MISUSE; DRUG MONITORING; DRUG RELEASE; DRUG SCREENING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG URINE LEVEL; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPIATE ADDICTION; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PRESCRIPTION; PRIMARY MEDICAL CARE; TREATMENT REFUSAL;

ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; CHRONIC PAIN; DELAYED-ACTION PREPARATIONS; FEMALE; GUIDELINE ADHERENCE; HUMANS; MALE; MIDDLE AGED; MORPHINE; OPIOID-RELATED DISORDERS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PRIMARY HEALTH CARE; QUESTIONNAIRES; RISK ASSESSMENT; RISK FACTORS; SUBSTANCE ABUSE DETECTION; UNITED STATES; YOUNG ADULT;

EID: 84862907895     PISSN: 15517489     EISSN: None     Source Type: Journal    
DOI: 10.5055/jom.2011.0088     Document Type: Article

References (33)

1. Chou R, Fanciullo GJ, Fine PG, et al.: Opioid treatment guidelines. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009; 10(2): 113-130.
2. Birnbaum HG, White AG, Reynolds JL, et al.: Estimated costs of prescription opioid analgesic abuse in the United States in 2001: A societal perspective. Clin J Pain. 2006; 22(8): 667-676. (Pubitemid 44434948)
3. Passik SD: Issues in long-term opioid therapy: Unmet needs, risks, and solutions. Mayo Clin Proc. 2009; 84(7): 593-601.
4. Denisco RA, Chandler RK, Compton WM: Addressing the intersecting problems of opioid misuse and chronic pain treatment. Exp Clin Psychopharmacol. 2008; 16(5): 417-428.
5. Gagnon AM, Kahan M, Srivastava A: Opioid use and abuse: Is there a problem? Clin J Pain. 2007; 23(8): 661-662. (Pubitemid 47462171)
6. Katz NP, Adams EH, Chilcoat H, et al.: Challenges in the development of prescription opioid abuse-deterrent formulations. Clin J Pain. 2007; 23(8): 648-660. (Pubitemid 47462170)
7. Passik SD, Kirsh KL: Forget the recipes: Let's talk data. Pain Med. 2009; 9(12): 261-265. (Pubitemid 351285424)
8. Ives TJ, Chelminski PR, Hammett-Stabler CA, et al.: Predictors of opioid misuse in patients with chronic pain: A prospective cohort study. BMC Health Serv Res. 2006; 6: 46-55.
9. Fleming MF, Balousek SL, Klessig CL, et al.: Substance use disorders in a primary care sample receiving daily opioid therapy. J Pain. 2007; 8(7): 573-582. (Pubitemid 46991033)
10. Gourlay DL, Heit HA, Almahrezi A: Universal precautions in pain medicine: A rational approach to the treatment of chronic pain. Pain Med. 2005; 6(2): 107-112. (Pubitemid 40590522)
11. Gianutsos LP, Safranek S, Huber T: Clinical inquiries: Is there a well-tested tool to detect drug-seeking behaviors in chronic pain patients? J Fam Pract. 2008; 57(9): 609-610.
12. Chou R, Fanciullo GJ, Fine PG, et al.: Opioids for chronic noncancer pain: Prediction and identification of aberrant drug-related behaviors: A review of the evidence for an American Pain Society and American Academy of Pain Medicine Clinical Practice Guideline. J Pain. 2009; 10(2): 131-146.
13. King Pharmaceuticals®, Inc: Avinza [Package Insert]. Bristol, TN: King Pharmaceuticals®, Inc, April 2008.
14. Brown J, Setnick B, Lee K, et al.: Effectiveness and safety of morphine sulfate extended-release capsules in patients with chronic, moderate-to-severe pain in a primary care setting. J Pain Res. In press.
15. Butler SF, Fernandez K, Benoit C, et al.: Validation of the revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R). J Pain. 2008; 9(4): 360-372.
16. Innovacon, Inc.: Multi-CLIN™ Drug Screen Test Device [Package Insert]. San Diego, CA: Innovacon, Inc, October 2006.
17. Gourlay DL, Heit HA, Caplan YH: Urine Drug Testing in Clinical Practice: Dispelling the Myths and Designing Strategies. Stamford, CT: Pharmacom Group, 2006: 1-25; Vol. 3.
18. Cleeland CS, Ryan KM: Pain assessment: Global use of the Brief Pain Inventory. Ann Acad Med Singapore. 1994; 23(2): 129-138.
19. Manchikanti L, Atluri S, Trescot AM, et al.: Monitoring opioid adherence in chronic pain patients: Tools, techniques, and utility. Pain Physician. 2008; 11: S155-S180. (Pubitemid 351682084)
20. Heit HA, Gourlay DL: Urine testing in pain medicine. J Pain Symptom Manage. 2004; 27(3): 260-266.
21. Compton P: The role of urine toxicology in chronic opioid analgesic therapy. Pain Manag Nurs. 2007; 8(4): 166-172.
22. Moeller KE: Urine drug screening: Practical guide for clinicians. Mayo Clin Proc. 2008; 83(1): 66-76.
23. Reisfield GM, Salazar E, Bertholf RL: Rational use and interpretation of urine drug testing in chronic opioid therapy. Ann Clin Lab Sci. 2007; 37(4): 301-314. (Pubitemid 350105930)
24. Michna E, Jamison RN, Pham L-D, et al.: Urine toxicology screening among chronic pain patients on opioid therapy: Frequency and predictability of abnormal findings. Clin J Pain. 2007; 23(2): 173-179. (Pubitemid 46145464)
25. Manchikanti L, Manchukonda R, Pampati V, et al.: Does random urine drug testing reduce illicit drug use in chronic pain patients receiving opioids? Pain Physician. 2006; 9: 123-129.
26. Gilbert JW, Wheeler GR, Mick GE, et al.: Urine drug testing in the treatment of chronic noncancer pain in a Kentucky private neuroscience practice: The potential effect of Medicare benefit changes in Kentucky. Pain Physician. 2010; 13: 187-194.
27. Manchikanti L, Pampati V, Damron KS, et al.: Prevalence of illicit drug use in patients without controlled substance abuse in interventional pain management. Pain Physician. 2003; 6(2): 173-178. (Pubitemid 36974909)
28. Sullivan MD, Edlund MJ, Fan MY, et al.: Risks for possible and probable opioid misuse among recipients of chronic opioid therapy in commercial and Medicaid insurance plans: The TROUP study. Pain. 2010; 150(2): 332-339.
29. Fishbain DA, Cole B, Lewis J, et al.: What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. Pain Med. 2008; 9(4): 444-459. (Pubitemid 351722518)
30. Starrels JL, Becker WC, Alford DP, et al.: Systematic review: Treatment agreements and urine drug testing to reduce opioid misuse in patients with chronic pain. Ann Intern Med. 2010; 152: 712-720.
31. Jamison RN, Ross EL, Michna E, et al.: Substance misuse treatment for high-risk chronic pain patients on opioid therapy: A randomized trial. Pain. 2010; 150(3): 390-400.
32. Gourlay DL, Heit HA: Pain and addiction: Managing risk through comprehensive care. J Addict Dis. 2008; 27(3): 23-30.
33. Gourlay DL, Heit HA: Universal precautions revisited: Managing the inherited pain patient. Pain Med. 2009; 10 (Suppl 2): S115-S123.